Form 4: Director Susan Shiff Receives Tvardi Therapeutics Options

Director Susan Shiff was granted 6,000 stock options in Tvardi Therapeutics, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Susan Shiff received a grant of 6,000 stock options for Tvardi Therapeutics, Inc. (TVRD) common stock.
• The options have an exercise price of $2.78 per share.
• The grant date for the transaction was June 9, 2026.
• The options are scheduled to expire on June 8, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial strategy.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $2.78 exercise price.
• Vesting is contingent upon the director's continuous service through the vesting date.

Future Outlook

The options vest in full on the earlier of June 9, 2027, or the date of the issuer's next annual meeting of stockholders, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to attract and retain board expertise.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for small-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 9, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Tvardi Therapeutics, TVRD, Form 4, Insider Trading, Stock Options, Director Compensation